| Metric | Value | Detail |
|---|---|---|
| Revenue | $44.3B | +5.7% YoY |
| Net income | $6.5B | 14.7% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 18.2% | Operating income / revenue |
| Return on equity | 12% | Net income / equity |
| Return on assets | 8% | Net income / assets |
| Revenue growth (YoY) | +5.7% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +0.5% | Compound annual |
| Diluted EPS | $3.73 | FY2025 |
| Debt-to-equity | 0.25 | Long-term debt / equity |
| Current ratio | 1.58 | Current assets / liabilities |
| Cash & equivalents | $8.5B | Balance sheet |
| Total assets | $86.7B | FY2025 year-end |
| Shareholders’ equity | $52.8B | FY2025 year-end |
| Share price | $93.93 | Delayed · 2026-07-10 |
| Market cap | $163.6B | Price × shares outstanding |
| P/E ratio | 25.1 | Market cap / net income |
| P/S ratio | 3.7 | Market cap / revenue |
| Dividend yield | 2.56% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
ABBOTT LABORATORIES (ABT) stock fundamentals
ABBOTT LABORATORIES (ABT) reported $44.3B in revenue and $6.5B in net income in fiscal 2025, a 14.7% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $163.6B at a delayed share price. It scores 44/100 on WealthyBud's Investor Score, ranking #60 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$44.3B
▲ +5.7% YoY
Net income
$6.5B
14.7% net margin
Market cap
$163.6B
Price $93.93 · delayed
P/E ratio
25.1
Price / earnings
Return on equity
12%
Net income / equity
Investor Score
44/100
#60 of 100 covered
ABBOTT LABORATORIES fundamentals at a glance
The table summarizes ABBOTT LABORATORIES's key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is ABBOTT LABORATORIES?
ABBOTT LABORATORIES runs a 14.7% net margin and n/a gross margin in fiscal 2025, turning $44.3B of revenue into $6.5B of profit. Return on equity is 12% and return on assets 8%.
Is ABBOTT LABORATORIES growing?
ABBOTT LABORATORIES's revenue changed +5.7% in fiscal 2025 and compounded at +0.5% a year over three years, reaching $44.3B. Diluted earnings per share were $3.73 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $43.1B | n/a |
| 2022 | $43.7B | +1.3% |
| 2023 | $40.1B | -8.1% |
| 2024 | $42.0B | +4.6% |
| 2025 | $44.3B | +5.7% |
How is ABBOTT LABORATORIES valued?
ABBOTT LABORATORIES carries a market capitalization of $163.6B at a delayed share price of $93.93, trading at a 25.1 price-to-earnings ratio and 3.7 price-to-sales with a 2.56% dividend yield. Its Value subscore is 61/100 across the covered universe.
How financially healthy is ABBOTT LABORATORIES?
ABBOTT LABORATORIES ended fiscal 2025 with $8.5B in cash, a debt-to-equity ratio of 0.25 and a current ratio of 1.58. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is ABBOTT LABORATORIES's Investor Score?
ABBOTT LABORATORIES scores 44/100 on WealthyBud's Investor Score, #60 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
44/100
#60 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
ABBOTT LABORATORIES (ABT) stock FAQ
How much revenue does ABBOTT LABORATORIES make?
ABBOTT LABORATORIES (ABT) reported $44.3B in revenue in fiscal 2025, +5.7% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +0.5% a year.
Is ABBOTT LABORATORIES profitable?
Yes. ABBOTT LABORATORIES earned $6.5B in net income in fiscal 2025, a 14.7% net margin. Its return on equity was 12% and return on assets 8%, based on figures from its latest 10-K.
How fast is ABBOTT LABORATORIES growing?
ABBOTT LABORATORIES's revenue changed +5.7% year over year in fiscal 2025 and compounded at +0.5% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 25/100 versus the covered universe.
What is ABBOTT LABORATORIES's market cap and P/E ratio?
ABBOTT LABORATORIES has a market capitalization of $163.6B at a delayed share price of $93.93, trading at a price-to-earnings ratio of 25.1 and price-to-sales of 3.7. Its dividend yield is 2.56%. Prices are delayed and illustrative.
What is ABBOTT LABORATORIES's WealthyBud Investor Score?
ABBOTT LABORATORIES scores 44/100, ranking #60 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (25), profitability (41), returns on capital (33), balance-sheet strength (77) and value (61). It is a research opinion, not investment advice.
Where does this ABBOTT LABORATORIES financial data come from?
Fundamentals come from ABBOTT LABORATORIES's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from ABBOTT LABORATORIES’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.